...long-term opioid treatment and for which alternative treatment options are inadequate Epigenomics AG (Xetra:ECX) / Polymedco Inc....

...Epigenomics and Polymedco Inc. (Cortlandt Manor, N.Y.) launched Epigenomics’ Epi proColon blood-based colorectal cancer screening test in...
...methylated DNA of the septin 9 gene in blood plasma by real-time PCR. Epigenomics and Polymedco...

...a PMA from Epigenomics for its Epi proColon blood-based colorectal cancer screening test. Epigenomics and Polymedco Inc....

...approved a PMA for its Epi proColon blood-based colorectal cancer (CRC) screening test. Epigenomics and Polymedco Inc....
...next few weeks, but did not disclose the list price. He said the company and Polymedco...

...9 gene in blood plasma. Epigenomics markets the test in Europe. Last October, Epigenomics granted Polymedco Inc....

...risks (see BioCentury, March 31). Epigenomics markets the test in Europe. Last October, Epigenomics granted Polymedco Inc....

...NYSE:ABBV) ABT-450 plus ritonavir/ABT-267/ABT-333 with or without ribavirin HCV infection Submit NDA 2Q14 Epigenomics AG (Xetra:ECX)/Polymedco Inc....

...the Septin 9 gene in blood plasma. Epigenomics markets in Europe. In October, Epigenomics granted Polymedco Inc....

...FDA sent a tentative date of March 25 for the meeting. In October, Epigenomics granted Polymedco Inc....

...Panel of the Medical Devices Advisory Committee to discuss the PMA. In October, Epigenomics granted Polymedco Inc....